ONO 8711 / Ono Pharma - LARVOL DELTA

Shugan Decoction Ameliorated WAS-Induced Abnormal Colonic Motility in Rats by Inhibiting Colonic TRPV4-PGE2 Signaling. (PubMed, Neurogastroenterol Motil) - "SGD can ameliorate dysmotility of colonic longitudinal muscle and visceral hypersensitivity caused by WAS maybe by reducing the release of PGE2 and decreasing the expression of TRPV4 and EP1."

Journal • Preclinical • Gastrointestinal Disorder • Immunology • Pain • TRPV4

Prostaglandin E2 and Receptors: Insight Into Tumorigenesis, Tumor Progression, and Treatment of Hepatocellular Carcinoma. (PubMed, Front Cell Dev Biol) - "For the treatment of hepatocellular carcinoma, there are drugs such as T7 peptide and EP1 antagonist ONO-8711 targeting Cox-2/PGE2 axis to inhibit tumor progression. In conclusion, PGE2 has been shown to be a traditional target with pleiotropic effects in tumorigenesis and progression of HCC that could be used to develop a new potential clinical impact. For the treatment study focusing on the COX-PGE2 axis, the exclusive usage of non-steroidal anti-inflammatory agents (NSAIDs) or COX-2-inhibitors may be replaced by a combination of selective EP antagonists and traditional anti-tumoral drugs to alleviate severe side effects and achieve better outcomes."

Journal • Review • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Solid Tumor

[VIRTUAL] Determination of the Prostanoid Receptor Subtype Involved in Treprostinil-Induced Cough in Guinea Pigs (ATS-I 2020) - "In contrast, the prostanoid EP 1 receptor antagonist ONO-8711, the prostanoid EP 2 receptor antagonist PF-04418948, the prostanoid EP 3 receptor antagonist L-798,106, and the prostanoid DP 1 receptor antagonist BW A868C, each had no effect on TRE-induced cough. We demonstrated that the IP receptor is the dominant prostanoid receptor subtype involved in nebulized TRE-induced cough in guinea pigs. Additionally, the cough response involves the neurokinin pathway through activation of NK 1 tachykinin containing sensory nerves."

Hypertension • Pulmonary Arterial Hypertension

Synergetic Effect of EP1 Receptor Antagonist and (-)-Epigallocatechin-3-gallate in Hepatocellular Carcinoma. (PubMed, Pharmacology) - "ONO-8711 significantly inhibited PGE2-induced HCC proliferation while increased the inhibitory effect of EGCG on HCC cell viability and migration ability compared with EGCG alone. These findings suggest that a combination of ONO-8711 and EGCG is a potential treatment for HCC therapy."

Journal

Determination of the Prostanoid Receptor Subtype Involved in Treprostinil-Induced Cough in Guinea Pigs (ATS 2020) - "In contrast, the prostanoid EP1 receptor antagonist ONO-8711, the prostanoid EP2 receptor antagonist PF-04418948, the prostanoid EP3 receptor antagonist L-798,106, and the prostanoid DP1 receptor antagonist BW A868C, each had no effect on TRE-induced cough. We demonstrated that the IP receptor is the dominant prostanoid receptor subtype involved in nebulized TRE-induced cough in guinea pigs. Additionally, the cough response involves the neurokinin pathway through activation of NK1 tachykinin containing sensory nerves."

Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

EP2 Receptor Blockade Attenuates COX-2 Upregulation During Intestinal Inflammation. (PubMed, Shock) - "...PGE2 upregulated COX-2 in IEC-6 enterocytes, and this response was blocked by the EP2 antagonist PF-04418948, but not by the EP1 antagonist ONO-8711 or EP4 antagonist E7046. In the neonatal rat model of NEC, EP2 antagonist and low dose of COX-2 inhibitor Celecoxib, but not EP1 antagonist, reduced NEC pathology as well as COX-2 mRNA and protein expression. In the adult mouse endotoxemia and cecal ligation/puncture models, EP2, but not EP1 genetic deficiency decreased COX-2 expression in the intestine. Our results indicate that the EP2 receptor plays a critical role in the positive feedback regulation of intestinal COX-2 by its end-product PGE2 during inflammation and may be a novel therapeutic target in the treatment of NEC."

Journal

Endothelin-1 Elicits TRP-Mediated Pain in an Acid-Induced Oral Ulcer Model. (PubMed, J Dent Res) - "...Spontaneous nociceptive behavior in oral ulcer model rats was inhibited by swab applications of BQ-788 (ET receptor antagonist), ONO-8711 (prostanoid receptor EP antagonist), and HC-030031 (TRPA1 antagonist)...The TRPV4-mediated allodynia component seems to be independent of endothelin signaling. These findings highlight the potential of endothelin signaling blockers as effective analgesic approaches for oral ulcer patients."

Journal